Search results
459 Results for 'Therapeutics'
- Technologies (65)
- Collaborations (4)
- Team (0)
- News (307)
- Pages (0)
- Multimedia (83)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 65
-
GC Therapeutics: Changing the Future of Cell Therapies
GC Therapeutics (GCTx) is applying their stem cell-engineering TFome platform to overcome barriers in the development and manufacturing of cell therapies to improve patient access across a broad range of disease areas. -
Injectable Hydrogel Adhesive for Improved Muscle Regeneration
A super-strong, stretchy, and self-healing biomaterial that adheres to muscles and helps them heal faster after injury. -
Ropirio: Novel Treatments Targeting the Lymphatic System
Ropirio is commercializing the world’s first drug that directly targets and reactivates lymph vessels, a portfolio of other lymph-targeting small molecules, and a preclinical platform for discovering more. -
DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition.
Collaborations 4
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss Brain Targeting Program
Advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics. -
i3 Center: Biomaterials to Create T Cell Immunity
Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.
News 307
Multimedia 83
-
Video/AnimationThe End of Aging—And Extinction | George Church, Ph.D. on Longevity, Dire Wolves, and Woolly MammothsWhat if aging was optional—and extinction reversible? In this episode of Ignition Sequence, Wyss Core Faculty member and geneticist and biotech pioneer, George Church, Ph.D., joins host Dylan Bohbot to explore the frontiers of gene therapy, de-extinction, and the future of human health. A founding scientist behind the Human Genome Project, and co-founder of Colossal... -
Video/Animation20-ish Questions with Samir Mitragotri20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Samir Mitragotri, a Core Faculty member of the Wyss Institute as well as a Professor of Bioengineering and Biologically Inspired Engineering at the Harvard John A. Paulson School... -
Audio/PodcastSeqVerify: A New Easily Accessible Tool for Comprehensive Cell Line Quality Assessment – The Stem Cell ReportDuring the last decade, advances in genome editing and pluripotent stem cell (PSC) culture have let researchers generate edited PSC lines to study a wide variety of biological questions. However, abnormalities in cell lines such as aneuploidy, mutations, on-target and off-target editing errors, and microbial contamination can arise during PSC culture or due to undesired... -
Video/AnimationDoriNano – Improved DNA Origami Nanodelivery to Fight Cancer and Other DiseasesWe’re developing DNA Origami nanodelivery, which is transforming nanoparticle industry. Developed at the Dana Farber Cancer Institute and the Wyss Institute at Harvard University, this innovative approach overcomes the challenges of other nanoparticles, offering stability, high drug loading capacity, nano-scale control of cargo spacing, and more – making it a highly customizable solution for delivering... -
Video/AnimationDeep-dive Molecular Blueprinting of Therapeutic Nanostructures | Anastasia ErshovaAnastasia Ershova, a scientist at the Wyss, introduces the innovative field of bionanotechnology. In this talk from LabWeek Field Building, she explores how this cutting-edge science is revolutionizing therapeutics and diagnostics by building molecules that interact with the body in novel ways. Ershova discusses DNA nanotechnology, where DNA is used as a material to create... -
Video/AnimationAminoX: Making Better Protein Drugs, Quicker and CheaperA synthetic biology and advanced chemistry platform that efficiently incorporates non-standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University